葡萄糖类-1激动剂和常见手术程序:术前和术后风险和并发症
Troy B Amen1, Lina I Ibrahim1, Stephen M Gillinov2
1Department of Orthopaedic Surgery, Hospital for Special Surgery, New York, NY.
The Journal of hand surgery
|October 7, 2025
概括
类似葡萄糖-1 (GLP-1) 受体激动剂对于接受手术的患者是安全的. 使用这些药物并没有增加术后并发症,重新手术或再入院率.
科学领域:
- 内分泌学 在内分泌学.
- 外科手术的结果
- 药理学 药理学是指药理学的学科.
背景情况:
- 葡萄糖类-1 (GLP-1) 受体激活剂对于管理2型糖尿病和肥胖至关重要.
- 它们对手部手术后术后结果的影响尚不清楚.
研究的目的:
- 评估手术前GLP-1激动剂在接受常见手术的患者中使用的安全性.
- 评估对术后并发症,再入院和重新手术的影响.
主要方法:
- 一个大型保险索赔数据库 (2015-2022) 的回顾性分析.
- 在六种常见的手术中,GLP-1激动剂使用者与非使用者的倾向性得分匹配 (1:4).
- 术后感染,90天再入院,90天因感染重新手术和2年复查率的分析.
主要成果:
- 使用GLP-1激动剂的患者患上术后感染的几率相等或更低,包括手术部位感染和伤口脱光.
- 肺炎,急性损伤,血瘤,肺栓塞和深静脉血栓形成的风险较低.
- 显著降低所有原因的90天再入院风险;同等的90天的感染再手术和2年的所有原因修复率.
结论:
- 手术前使用GLP-1激动剂与手术后90天术后感染的风险增加无关.
- 接受GLP-1激动剂治疗的患者经历了同等或更低的整体外科手术后并发症,重新手术和再入院率.
相关概念视频
Hypoglycemia and Glucagon
830
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
830
Glucagon-like Receptor Agonists
841
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
841
Oral Hypoglycemic Agents: Glinides
598
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
598
Peripheral Artery Disease V: Postoperative Nursing Management
376
During the postoperative period, it is crucial to focus on maintaining circulation, identifying and managing potential complications, and planning for discharge.Nursing AssessmentVital signs monitoring: Regularly monitor vital signs, including blood pressure, heart rate, respiratory rate, and temperature, to detect early signs of complications such as bleeding and infection.Circulation assessment: Monitor pulses, perform Doppler assessments, and check capillary refill, color, temperature, and...
376
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
523
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
523
Oral Hypoglycemic Agents: Biguanides and Glitazones
583
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
583


